Earlier Diagnosis of Progressive Disease during Bevacizumab Treatment Using O-(2-F-Fluorethyl)-L-Tyrosine Positron Emission Tomography in Comparison with Magnetic Resonance Imaging
Antiangiogenic treatment using bevacizumab in brain tumor patients may cause difficulties in the diagnosis of tumor progression (ie, nonenhancing tumor progression). Newly defined criteria for treatment assessment and diagnosis of tumor progression (ie, RANO [Response Assessment in Neuro-Oncology] c...
Saved in:
Main Authors: | Norbert Galldiks, Marion Rapp, Gabriele Stoffels, Veronika Dunkl, Michael Sabel, Karl-Josef Langen |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2013-07-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.2310/7290.2013.00051 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Imaging of Non— or Very Subtle Contrast-Enhancing Malignant Gliomas with [C]-Methionine Positron Emission Tomography
by: Norbert Galldiks, et al.
Published: (2011-11-01) -
Feasibility of Vascular Endothelial Growth Factor Imaging in Human Atherosclerotic Plaque Using Zr-Bevacizumab Positron Emission Tomography
by: Reza Golestani, et al.
Published: (2013-06-01) -
Radiochemistry for positron emission tomography
by: Jian Rong, et al.
Published: (2023-06-01) -
Positron Emission Tomography Scanning and Gastroenterology
by: Jean-Luc Urbain, et al.
Published: (2008-01-01) -
Positron emission tomography tracers for synucleinopathies
by: Jie Xiang, et al.
Published: (2025-01-01)